BridgeBio to Unveil Phase 3 Data for Infigratinib in Achondroplasia at ICCBH
Event summary
- BridgeBio will present late-breaking Phase 3 PROPEL 3 trial results for oral infigratinib in children with achondroplasia at ICCBH 2026 on June 28.
- Additional data includes quality of life findings, early intervention research, and educational resources through MyAchonJourney.
- The company will also share findings from the CLARIFY disease monitoring study for autosomal dominant hypocalcemia (ADH) type 1 and type 2.
The big picture
BridgeBio’s presentation of Phase 3 data for infigratinib marks a critical milestone in the development of treatments for achondroplasia, a rare genetic condition affecting bone growth. The company’s decentralized model aims to streamline drug development for small patient populations, but success will depend on demonstrating efficacy and securing regulatory approval. The broader biopharmaceutical industry is watching closely, as advancements in genetic science continue to drive innovation in treating underserved conditions.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 data will support a regulatory submission for infigratinib, accelerating its path to market.
- Market Potential
- The commercial viability of infigratinib given the small patient population and high development costs for rare diseases.
- Competitive Landscape
- How BridgeBio’s progress compares to other companies developing treatments for achondroplasia, such as BioMarin’s vosoritide.